Labcorp Perspectives: Oncology

What does nuclear grading really reveal in the modern molecular era of endometrial cancer care? In this episode of Labcorp Perspectives Oncology , host Dr. Rebecca Previs, Senior Director of Medical Affairs, sits down with gynecologic pathologist Dr. Tricia Numan and anatomic and molecular pathologist Dr. Kyle Strickland to unpack the surprising findings from their USCAP-presented study. Step into...

In this compelling episode of Labcorp Perspectives Oncology , host Dr. Rebecca Previs is joined by innovators Dr. Angeles Alvarez Secord and Dr. Aine Clements to discuss high-impact data on endometrial cancer, focusing on the landmark GOG258 trial through the lens of modern molecular classification. The trio explores how integrating single-gene testing for markers such as POL-E, mismatch repair, a...

In this episode of Labcorp Perspectives Oncology , host Dr. Rebecca Previs welcomes Dr. Brian Caveney, Labcorp’s Chief Medical and Scientific Officer, to unpack findings from the Pulse of the Oncologist report—a nationwide survey capturing the real-world perspectives of 152 oncologists across practice settings. Together, Dr. Rebecca Previs and Brian Caveney dive into the pressing issues that shape...

How are companion diagnostics (CDXs) transforming the landscape of precision oncology? In this episode of Labcorp Perspectives Oncology , host Dr. Rebecca Previs welcomes CDX expert Dawn McHugh, Director of Precision Oncology CDx at Labcorp, for a deep dive into the evolving world of companion diagnostics. You’ll learn what defines a true CDX, how it differs from other biomarker tests, and why int...

In this episode of Labcorp Perspectives Oncology , host Dr. Rebecca Previs is joined by Dr. Kyle Strickland, Director of Medical Affairs and pathologist at Labcorp, and Dr. Erin Newburn, field application scientist and genomicist, for a deep dive into tissue stewardship and the pivotal role of FFPE specimens in precision oncology. Together, the team demystifies how formalin-fixed paraffin-embedded...

In this insightful episode of Labcorp Perspectives Oncology , host Dr. Rebecca Previs sits down with Dr. Mark Sausen, Labcorp's Head of Technology and Innovation, to break down a cutting-edge Phase II clinical trial exploring perioperative immunotherapy for resectable diffuse pleural mesothelioma, a rare and aggressive cancer. Hear firsthand how the introduction of immune checkpoint blockade and a...

In this episode of Labcorp Perspectives Oncology , host Dr. Rebecca Previs connects with Suzanne Garner, Senior Director of Strategic Partnerships at Outcomes4Me, to spotlight her remarkable journey as a breast cancer patient, advocate, and now leader in digital health. Suzanne shares her personal story, from an unexpected diagnosis and navigating overwhelming choices, to the pivotal discovery tha...

In this episode of Labcorp Perspectives Oncology , host Dr. Rebecca Previs sits down with colleague and pathologist Dr. Kyle Strickland to explore the complexities of ovarian cancer and the evolving science shaping its diagnosis and treatment. Together, they discuss how ovarian cancer is often misunderstood as a single disease, the importance of accurately classifying its subtypes, and the critica...

A Real Story of Hope, Testing, and Targeted Care. In this episode of Labcorp Perspectives: Oncology , host Dr. Rebecca Previs speaks with Ken Schlosser about how biomarker testing informed his care plan after a stage IV lung cancer diagnosis in 2019. Ken shares how a routine trip to the ER led to the discovery of an ALK+ alteration, and how comprehensive genomic profiling through OmniSeq helped gu...

Precision oncology is evolving fast, and staying ahead means rethinking how we test, monitor, and treat cancer. In this episode of Labcorp Perspectives: Oncology , host Dr. Rebecca Previs sits down with Dr. Michelle Green, senior manager of oncology genomics, to talk about the major highlights from the ASCO Annual Meeting. They explore Labcorp’s HER2 expression study in breast cancer, which found...

Tumor biology is rewriting the rules of cancer treatment. In this episode of Labcorp Perspectives: Oncology , host Dr. Rebecca Previs talks with Dr. Heidi Ko, Director of Medical Affairs at Labcorp and a breast medical oncologist, about the rapid evolution of tumor-agnostic therapies and HER2-targeted treatment strategies. They unpack what these FDA approvals actually mean in clinical practice, wh...

Genetic testing is no longer optional — it’s essential. Welcome to the first episode of Labcorp Perspectives: Oncology, where host Dr. Rebecca Previs sits down with Sarah Young, a genetic counselor and Clinical Program Manager for Oncology at Labcorp, to talk about the growing importance of genetic testing in prostate cancer care. Sarah shares insights from the recent American Urological Associati...